Background: Novel agents are changing the treatment of relapsed or refractory Hodgkin lymphoma (HL). Nevertheless, high-dose chemotherapy and autologous stem-cell transplantation (ASCT) are considered standard of care in eligible patients. To identify patients who could benefit most from novel therapeutic approaches, we investigated a comprehensive set of risk factors (RFs) for survival after ASCT.
Introduction
Salvage chemotherapy followed by high-dose chemotherapy (HDCT) and autologous stem-cell transplantation (ASCT) is the current standard treatment of eligible relapsed/refractory Hodgkin lymphoma (HL) patients [1, 2] . About 50% of patients relapse again and consecutively often die due to progression of disease and its complications [3] . More recently, the prognosis of relapsed/refractory HL improved with the advent of effective novel targeted agents such as brentuximab vedotin (BV) [4] . In addition, check-point inhibitors such as nivolumab [5] or pembrolizumab have shown impressive results in a variety of cancers including HL and are well-tolerated, highly effective therapeutic options.
These agents improve the treatment of relapsed/refractory HL, either by intensifying salvage therapy or as consolidative therapy after ASCT. The latter approach has been investigated in the randomized AETHERA trial, where BV given for up to 1 year post-ASCT resulted in a superior progression-free survival (PFS) when compared with placebo [6] . Anti-programmed-death receptor 1 (PD1) antibodies, cellular therapies or a tandem ASCT [7, 8] constitute potential alternative modalities to consolidate HDCT in high-risk patients.
Continuous treatment with an active agent holds the risk of developing undesired side-effects and constitutes a considerable challenge for patients, caregivers and health services. Hence, it is important to identify those patients at high risk for progression or relapse of disease after ASCT to determine who would benefit from a consolidation therapy. On the other hand, patients at low risk for consecutive relapse might be suitable for less intensive approaches.
To date, there are no widely used and accepted prognostic scores for PFS and overall survival (OS) after ASCT. This international prognostic modeling study thus aimed at identifying a combination of risk factors (RFs) forming a comprehensive and validated prognostic score. Such a score will allow stratifying patients in both, routine clinical practice and upcoming clinical trials to further evaluate novel therapeutic approaches.
Methods

Study design and population
In part I, a prognostic score for PFS after ASCT was developed from multivariable analysis of 23 potential RFs (RFp). Included patients with relapsed/refractory HL undergoing an ASCT were primarily treated in the GHSG first-line trials HD10-12 ('G4', n ¼ 82) and HD13-15 ('G5', n ¼ 219) or the trials in relapsed/refractory HL HDR1 (arm B only, n ¼ 40), HDR2 (n ¼ 197) and LYSA H96 (single ASCT only, n ¼ 118) (Figure 1 ). Validation in part II was carried out in an independent sample of patients treated with an ASCT in the US at the MSKCC (n ¼ 318) and at Danish hospitals (n ¼ 71). To estimate the real-world distribution of Figure 1 . Flowchart of data sources and analyses sets. r/r HL: relapsed or refractory Hodgkin lymphoma; HDR1: GHSG HDR1 trial for r/r HL; HDR2: European HDR2 trial for r/r HL, H96: French H96 trial for r/r HL; GHSG G4: first-line trials HD10-12; GHSG G5: first-line trials HD13-15; MSKCC: patients treated for r/r HL at the MSKCC; Denmark: patients treated for r/r HL at various hospitals in Denmark.
risk groups and Kaplan-Meier curves, we finally analyzed a combined sample of G4, G5, MSKCC and Danish patients, who have been treated for relapsed/refractory HL predominantly in routine clinical care.
End points
The primary end point was PFS defined as the interval between ASCT and the earliest date of the following events: progression of HL, relapse of HL or death from any cause. A secondary end point was OS defined as the interval between ASCT and date of death from any cause. If none of the events were observed, the end points were censored at the date of last information on tumor status (PFS) or survival (OS).
Potential RF
Information on a comprehensive set of clinical RFs in relapsed/refractory HL was compiled by chart and database review. Most of these RFp have been previously described [9] and are summarized in Figure 2 and supplementary List S1, available at Annals of Oncology online.
Statistical measures
In part I of this study, descriptive statistics and uni-/multi-variable analyses of RFp with Cox proportional hazards regression for PFS after ASCT were applied. Each RFp was pre-tested by Cox regression with adjustment for the 'Josting-score' (sum of the RF clinical stage III/IV, anemia and TTR 12 months, range 0-3) [10] with P < 0.10. The resulting preselected RFp were tested in a final multivariable Cox model (P < 0.05) and evaluated for clinical practicability. Non-significant RFp were removed from the model and, if hazards were non-proportional, the respective RFp modified. The Cox regression analyses were stratified for auxiliary variables (data source, age) and tests of significance were without correction for multiple testing. Sensitivity analysis and comparison of prognostic latent variable models with equal or different weights of RFs were carried out to check the robustness of the results.
In part II of this study, the prognostic score was validated in an independent sample by comparing HR and Kaplan-Meier curves of part II with part I. Of note, response to salvage therapy was measured by functional imaging instead of conventional CT scans in this cohort. The validation method, the handling of missing values and further important statistical details are described in the supplementary material, available at Annals of Oncology online.
Results
In part I of this analysis, 656 HL patients from France and Germany where analyzed while validation in part II was carried out in 389 patients from the US and Denmark with a median follow-up of 60 and 59 months after ASCT, respectively ( Figure 1 Figure 2 . Part I: hazard ratios of each potential risk factor with 95% confidence intervals in univariate analysis (left panel) and in multivariable analysis adjusted for the modified Josting score (right panel with 90% confidence interval for preselection of RF; CS, TTR and anemia omitted because these RF are part of the Josting score). All analyses with adjustment for data source and age 45 years as auxiliary variables; right panel with adjustment for the modified Josting-score (i.e. stage IV, TTR 12 months and anemia); HR, hazard ratio; LCL, lower confidence level; UCL, upper confidence level; nþ, number of patients with RF present; n, number of patients with data on RF available.
The vast majority of RFp analyzed in part I had significant impact on PFS with hazard ratios (HR) ranging from 1.39 to 2.22 ( Figure 2 , left side). In a next step, the multivariable analysis preselected ECOG 1, bulk 5 cm, an inadequate response to salvage chemotherapy, i.e. <partial remission (PR) by computed tomography (CT), and relapse in a radiotherapy (RT) field as further non-redundant RF (P < 0.1) in addition to the modified earlier risk score (Josting-score; Figure 2 , right side). Since we were aiming to develop a universally applicable prognostic score and RT in first-line treatment is only applied in a subset of patients, this RF was not further investigated due to its limited general relevance.
The multivariable cox regression analysis of the preselected RFs plus the three variables constituting the Josting-score confirmed the significance of all six RFs with exception of anemia (P ¼ 0.1851). The RF TTR 12 months violated the proportional hazards assumption and therefore was replaced by the comparable RF TTR 3 months. The final cox regression analysis confirmed the significance of all remaining five RFs for PFS after ASCT without any significant deviation from the assumption of proportional hazards. A prognostic score additively composed of the five RFs identified at least three distinct risk groups (Table 1) . Kaplan-Meier curves of PFS with the five single RFs and the respective risk groups in patients with complete data on the five factors are shown in supplementary Figure S1 , available at Annals of Oncology online.
A latent variable analysis accounting for missing values confirmed that all five RFs contributed significantly (P < Table S3 , available at Annals of Oncology online).
In part II of the analysis, the prognostic score was validated in an independent sample of 389 patients, in which ECOG was frequently missing due to a lack of documentation in older patient records. The missing values were imputed with a fully conditional specified logistic model as detailed in the Methods section and supplementary material, available at Annals of Oncology online. Cox regression of PFS was repeated and the prognostic score discriminated risk groups in part II exactly as well as in part I as shown by the almost identical HRs (Table 2) . Corresponding Kaplan-Meier curves in Figure 3 show excellent discrimination and comparable calibration in both samples with response to salvage therapy either measured by CT (part I) or functional imaging (part II).
Various sensitivity analyses including a complete-case analysis confirmed the validity of the prognostic score for PFS (supplementary Figure S2 and Table S4 , available at Annals of Oncology online).
A summary analysis of patients treated for relapsed/refractory HL predominantly in routine clinical care (subgroup of parts I and II, n ¼ 690, Figure 1 ) is shown in Figure 3C and Table 3 . Importantly, the size of each risk group is relevant and 17.6% of patients are at highest risk for progression of disease, while 22.4% fall into the lowest risk group. As shown in Figure 3D and Table 3 the novel prognostic score is also valid for OS after ASCT. n, number of patients with information on RF; PFS, progression-free survival after ASCT; OS, overall survival after ASCT; HR, hazard ratio; TTR, time to relapse; ECOG, Eastern Cooperative Oncology Group performance index.
Discussion
To allow a better judgement of risk in relapsed/refractory HL patients undergoing HDCT þ ASCT, we analyzed more than 20 RFs in an international cohort of 1045 patients. Multivariable analysis identified five significant and non-redundant RFs: TTR 3 months, stage IV, ECOG 1, bulk 5 cm at relapse and nonresponse to salvage chemotherapy (either <PR by CT or PETpositive residual disease). The sum of RFs present significantly discriminated different risk groups for both PFS and OS after ASCT. Discrimination and calibration of the risk score was confirmed in an independent clinical sample without any loss of precision or necessity of modification. In addition to PFS, OS after ASCT was predicted with the same high precision. The majority of the five RFs has been described earlier in smaller series, but has never been evaluated together in a larger sample. A short TTR after completion of first-line therapy representing aggressive tumor growth has frequently been described as RF for both, PFS and OS [9, 10] . Stage III and/or IV at relapse indicates wide spread lymphoma and has also been frequently reported as an adverse RF in relapsed/refractory HL [10] . In a prospective European trial in relapsed/refractory HL, patients with stage II and III disease at relapse had comparable outcomes [2] . Along these lines, we found that stage IV had a univariate HR of 1.90 compared with 1.39 for stage III/IV in part I of this study (Figure 2 ). Representing truly disseminated disease, stage IV at relapse seems to better discriminate high-risk patients.
When measured by CT, patients achieving <PR after salvage chemotherapy before HDCT were reported at high risk for relapse and death [9] . Residual disease detected by functional imaging, e.g. PET, was also associated with unfavorable outcome, often rendering conventional RFs insignificant [11] . Patients with PET-positive disease seem to benefit from normalization of PET-status before ASCT [12] . Validation in an external cohort with response to salvage therapy measured by functional imaging instead of conventional CT allowed evaluation of the prognostic score in the setting of two different imaging modalities in our analysis. Non-response to salvage defined either as <PR by CT or PET-positivity before ASCT likely reflects chemo-resistance of disease and interestingly PET-status does not overshadow the other RFs in our score.
Tumor bulk 5 cm has been investigated in the first-line setting but was rarely described as an adverse RF in relapsed/ Figure 2 ). Similarly, performance status at relapse indicative of the patients' overall constitution and tolerability of intensified therapy had only occasionally been evaluated as RF [9] . Measured as ECOG score it is associated with inferior outcome. As shown in Figure 2 , a variety of other RFs had significant impact on PFS in the univariate analysis but did not meet the selection criterion of P < 0.1 in the adjusted multivariable analysis. We interpret the combined final five RFs to represent five distinct dimensions of disease overshadowing other, non-significant RFs: aggressive tumor growth, disseminated disease extent, tumor volume, patients' constitution and chemo-sensitivity.
The present study has limitations which are common in this type of analysis: retrospective and collaborative in nature, data sources vary and there is considerable heterogeneity (supplementary Table S1 , available at Annals of Oncology online). In addition, there is a considerable amount of missing values in some RFs, mostly in ECOG performance status due to lack of specific documentation in the patients' files, which potentially introduces considerable bias to our analysis. These challenges were addressed with contemporary methods such as multiple imputation and accompanying sensitivity analyses, both, in parts I and II. None of the sensitivity analyses challenged our findings. As known from previous analysis, PFS and OS events may preclude ASCT and other patients are not eligible for such an intensified approach. These patients have an unfavorable prognosis and are not represented in our analysis, focusing on patients undergoing an ASCT.
Our study has several strengths: we analyzed almost all previously described RFs in the largest sample reported so far. With patients in parts I and II of the analysis treated in different clinical settings in Europe and the USA, results are considered generalizable and representative. The five RFs are easily available from routine clinical data and determination hence causes no additional effort or costs. Importantly, the score discriminated at least four risk groups of relevant size for both, PFS and OS. An entirely clinical prognostic score is universally applicable even in resource constraint settings and outside academic centers.
Progression of relapsed/refractory HL results in premature death in most cases; prognosis is especially poor in patients suffering from subsequent relapses [3] . This is also depicted in our analysis where a PFS event regularly translates into an OS event over time. Therefore, innovative therapeutic approaches and valid methods of risk stratification are urgently needed in those patients.
Intensification of salvage therapy with conventional agents did not improve outcome in the randomized European HDR2 trial [2] . In contrast, a tandem ASCT was reported to improve outcome of high-risk patients when compared with a single ASCT in indirect historic comparison [7] . Recently, the AETHERA investigators reported a more favorable 3-year PFS rate with BV consolidation for up to 1 year after ASCT in a cohort at an increased risk for relapse when compared with placebo [6] . In addition, immunotherapeutic approaches such as checkpoint-blockade showed encouraging results in relapsed/refractory HL and nivolumab recently approved by the FDA [5] . In this setting, a validated prognostic score rather than somewhat arbitrary selected single RFs allows to identify patients in whom potential benefits outweigh risks and costs associated with an active agent. Our score may be applied to select patients for, e.g. consolidative therapy in clinical practice but also to guide development of future strategies within clinical trials.
In conclusion, accurate and reliable risk stratification in patients with relapsed/refractory HL who successfully undergo ASCT can be achieved with the five easily available clinical RFs stage IV, TTR 3 months, bulk 5 cm, ECOG 1 and non-response to salvage, either measured as <PR by CT or PET-positivity.
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